Neural ECM and epilepsy

Progress in Brain Research

Volumn 214, Issue , 2014, Pages 229-262

  Pitkänen, Asla ^a,b   Ndode Ekane, Xavier E ^a   Łukasiuk, Katarzyna ^c   Wilczynski, Grzegorz M ^c   Dityatev, Alexander ^d   Walker, Matthew C ^e   Chabrol, Elodie ^e   Dedeurwaerdere, Stefanie ^f   Vazquez, Naiara ^f   Powell, Elizabeth M ^g  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF ANTWERP   (Belgium)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Autism; Epileptogenesis; Heparan sulfate proteoglycan; Imaging; LGI1; Matrix metalloproteinase; Tenascin; Urokinase

Indexed keywords

FORMYL PEPTIDE G PROTEIN COUPLED RECEPTOR; INTEGRIN; KININOGEN; LEUCINE RICH GLIOMA INACTIVATED 1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POTASSIUM CHANNEL KV1.1; PROTEIN; PROTEIN ADAM22; PROTEIN ADAM23; PROTEOCHONDROITIN SULFATE; PROTEOHEPARAN SULFATE; REELIN; STROMELYSIN; SUSHI REPEAT PROTEIN X LINKED 2; TENASCIN; TENASCIN R; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN; ANTICONVULSIVE AGENT;

ARTICLE; AUTISM; COMORBIDITY; DISEASE ASSOCIATION; EPILEPSY; EPILEPTOGENESIS; EXTRACELLULAR MATRIX; GENE MUTATION; HUMAN; INTERACTOME; MENTAL DISEASE; MOLECULAR BIOLOGY; NERVE CELL; NERVE CELL EXCITABILITY; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SATELLITE CELL; SCHIZOPHRENIA; SEIZURE; SIGNAL TRANSDUCTION; TEMPORAL LOBE EPILEPSY; ANIMAL; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTICONVULSANTS; EPILEPSY; EXTRACELLULAR MATRIX; HUMANS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR;

EID: 84916880379     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-63486-3.00011-6     Document Type: Chapter

References (196)

1. Abdallah M.W., Pearce B.D., Larsen N., Greaves-Lord K., Norgaard-Pedersen B., Hougaard D.M., et al. Amniotic fluid MMP-9 and neurotrophins in autism spectrum disorders: an exploratory study. Autism Res. 2012, 5:428-433.
2. Adams J.B., Audhya T., Mcdonough-Means S., Rubin R.A., Quig D., Geis E., et al. Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity. Nutr. Metab. (Lond.) 2011, 8:34.
3. Aguirre-Ghiso J.A. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene 2002, 21(16):2513-2524.
4. Bae M.H., Bissonette G.B., Mars W.M., Michalopoulos G.K., Achim C.L., Depireux D.A., et al. Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility. Exp. Neurol. 2010, 221:129-135.
5. Bae H.B., Tadie J.M., Jiang S., Park D.W., Bell C.P., Thompson L.C., Peterson C.B., Thannickal V.J., Abraham E., Zmijewski J.W. Vitronectin inhibits efferocytosis through interactions with apoptotic cells as well as with macrophages. J. Immunol. 2013, 190(5):2273-2281.
6. Bajor M., Michaluk P., Gulyassy P., Kekesi A.K., Juhasz G., Kaczmarek L. Synaptic cell adhesion molecule-2 and collapsin response mediator protein-2 are novel members of the matrix metalloproteinase-9 degradome. J. Neurochem. 2012, 122(4):775-788.
7. Barger S.W., Van Eldik L.J. S100 beta stimulates calcium fluxes in glial and neuronal cells. J. Biol. Chem. 1992, 267:9689-9694.
8. Bear M.F., Huber K.M., Warren S.T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004, 27:370-377.
9. Berg A.T., Berkovic S.F., Brodie M.J., Buchhalter J., Cross J.H., van Emde Boas W., Engel J., French J., Glauser T.A., Mathern G.W., Moshé S.L., Nordli D., Plouin P., Scheffer I.E. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010, 51(4):676-685.
10. Berry-Kravis E., Raspa M., Loggin-Hester L., Bishop E., Holiday D., Bailey D.B. Seizures in fragile X syndrome: characteristics and comorbid diagnoses. Am. J. Intellect. Dev. Disabil. 2010, 115:461-472.
11. Bilousova T.V., Rusakov D.A., Ethell D.W., Ethell I.M. Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. J. Neurochem. 2006, 97:44-56.
12. Bilousova T.V., Dansie L., Ngo M., Aye J., Charles J.R., Ethell D.W., et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 2009, 46:94-102.
13. Bissonette G.B., Bae M.H., Suresh T., Jaffe D.E., Powell E.M. Astrocyte-mediated hepatocyte growth factor/scatter factor supplementation restores GABAergic interneurons and corrects reversal learning deficits in mice. J. Neurosci. 2010, 30:2918-2923.
14. Bissonette G.B., Bae M.H., Suresh T., Jaffe D.E., Powell E.M. Selective prefrontal cognitive deficits in mice with altered cerebral cortical GABAergic interneurons. Behav. Brain Res. 2014, 259:143-151.
15. Bisulli F., Tinuper P., Avoni P., Striano P., Striano S., d'Orsi G., et al. Idiopathic partial epilepsy with auditory features (IPEAF): a clinical and genetic study of 53 sporadic cases. Brain 2004, 127:1343-1352.
16. Blatt G.J., Fatemi S.H. Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anat. Rec. (Hoboken) 2011, 294:1646-1652.
17. Bonora E., Beyer K.S., Lamb J.A., Parr J.R., Klauck S.M., Benner A., et al. Analysis of reelin as a candidate gene for autism. Mol. Psychiatry 2003, 8:885-892.
18. Brenneke F., Bukalo O., Dityatev A., Lie A.A. Mice deficient for the extracellular matrix glycoprotein tenascin-R show physiological and structural hallmarks of increased hippocampal excitability, but no increased susceptibility to seizures in the pilocarpine model of epilepsy. Neuroscience 2004, 124:841-855.
19. Brigman J.L., Padukiewicz K.E., Sutherland M.L., Rothblat L.A. Executive functions in the heterozygous reeler mouse model of schizophrenia. Behav. Neurosci. 2006, 120:984-988.
20. Brooks-Kayal A. Molecular mechanisms of cognitive and behavioral comorbidities of epilepsy in children. Epilepsia 2011, 52(Suppl. 1):13-20.
21. Cabungcal J.H., Steullet P., Morishita H., Kraftsik R., Cuenod M., Hensch T.K., et al. Perineuronal nets protect fast-spiking interneurons against oxidative stress. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:9130-9135.
22. Campbell D.B., D'oronzio R., Garbett K., Ebert P.J., Mirnics K., Levitt P., et al. Disruption of cerebral cortex MET signaling in autism spectrum disorder. Ann. Neurol. 2007, 62:243-250.
23. Canitano R. Epilepsy in autism spectrum disorders. Eur. Child Adolesc. Psychiatry 2007, 16:61-66.
24. Cascella N.G., Schretlen D.J., Sawa A. Schizophrenia and epilepsy: is there a shared susceptibility?. Neurosci. Res. 2009, 63:227-235.
25. Chabrol E., Popescu C., Gourfinkel-An I., Trouillard O., Depienne C., Senechal K., et al. Two novel epilepsy-linked mutations leading to a loss of function of LGI1. Arch. Neurol. 2007, 64:217-222.
26. Chabrol E., Navarro V., Provenzano G., Cohen I., Dinocourt C., Rivaud-Péchoux S., et al. Electroclinical characterization of epileptic seizures in leucine-rich, glioma-inactivated 1-deficient mice. Brain 2010, 133:2749-2762.
27. Chernova O.B., Somerville R.P., Cowell J.K. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene 1998, 17:2873-2881.
28. Chez M.G., Chang M., Krasne V., Coughlan C., Kominsky M., Schwartz A. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Behav. 2006, 8:267-271.
29. Chuang S.C., Zhao W., Bauchwitz R., Yan Q., Bianchi R., Wong R.K. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J. Neurosci. 2005, 25:8048-8055.
30. Corley M.J., Meyza K.Z., Blanchard D.C., Blanchard R.J. Reduced sulfate plasma concentrations in the BTBR T+tf/J mouse model of autism. Physiol. Behav. 2012, 107:663-665.
31. Cunningham O., Campion S., Perry V.H., Murray C., Sidenius N., Docagne F., Cunningham C. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Glia 2009, 57(16):1802-1814.
32. Czekay R.P., Aertgeerts K., Curriden S.A., Loskutoff D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 2003, 160(5):781-791.
33. Darnell J.C., Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat. Neurosci. 2013, 16:1530-1536.
34. Dedeurwaerdere S., Shultz S., Federico P., Engel J. Workshop on neurobiology of epilepsy appraisal: new systemic functional imaging technologies to study the brain in experimental models of epilepsy. Epilepsia 2014, 55(6):819-828.
35. Degryse B., Sier C.F., Resnati M., Conese M., Blasi F. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Lett. 2001, 505(2):249-254.
36. Deininger M.H., Trautmann K., Magdolen V., Luther T., Schluesener H.J., Meyermann R. Cortical neurons of Creutzfeldt-Jakob disease patients express the urokinase-type plasminogen activator receptor. Neurosci. Lett. 2002, 324(1):80-82.
37. Depositario-Cabacar D.F., Zelleke T.G. Treatment of epilepsy in children with developmental disabilities. Dev. Disabil. Res. Rev. 2010, 16:239-247.
38. Dityatev A., Fellin T. Extracellular matrix in plasticity and epileptogenesis. Neuron Glia Biol. 2008, 4:235-247.
39. Dutta S., Sinha S., Ghosh S., Chatterjee A., Ahmed S., Usha R. Genetic analysis of reelin gene (RELN) SNPs: no association with autism spectrum disorder in the Indian population. Neurosci. Lett. 2008, 441:56-60.
40. Dyck R.H., Bogoch I.I., Marks A., Melvin N.R., Teskey G.C. Enhanced epileptogenesis in S100B knockout mice. Brain Res. Mol. Brain Res. 2002, 106:22-29.
41. Dziembowska M., Pretto D.I., Janusz A., Kaczmarek L., Leigh M.J., Gabriel N., et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am. J. Med. Genet. A 2013, 161A:1897-1903.
42. East E., Baker D., Pryce G., Lijnen H.R., Cuzner M.L., Gverić D. A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am. J. Pathol. 2005, 167(2):545-554.
43. Edwards D., Jones P., Haramis H., Battle M., Lear R., Barnett D.J., Edwards C., Crawford H., Black A., Godden V. 99mTc-NC100692-a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation. Nucl. Med. Biol. 2008, 35:365-375.
44. Falo M.C., Fillmore H.L., Reeves T.M., Phillips L.L. Matrix metalloproteinase-3 expression profile differentiates adaptive and maladaptive synaptic plasticity induced by traumatic brain injury. J. Neurosci. Res. 2006, 84(4):768-781.
45. Fatemi S.H., Snow A.V., Stary J.M., Araghi-Niknam M., Reutiman T.J., Lee S., et al. Reelin signaling is impaired in autism. Biol. Psychiatry 2005, 57:777-787.
46. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E., Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997, 16(24):7279-7286.
47. Fisher R.S., van Emde Boas W., Blume W., Elger C., Genton P., Lee P., Engel J. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46(4):470-472.
48. Folsom T.D., Fatemi S.H. The involvement of Reelin in neurodevelopmental disorders. Neuropharmacology 2013, 68:122-135.
49. Frye R.E., Rossignol D., Casanova M.F., Brown G.L., Martin V., Edelson S., et al. A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel. Front. Public Health 2013, 1:31.
50. Fukata Y., Adesnik H., Iwanaga T., Bredt D.S., Nicoll R.A., Fukata M. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science 2006, 313:1792-1795.
51. Fukata Y., Lovero K.L., Iwanaga T., Watanabe A., Yokoi N., Tabuchi K., et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3799-3804.
52. Garcia-Nonell C., Ratera E.R., Harris S., Hessl D., Ono M.Y., Tartaglia N., et al. Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. Am. J. Med. Genet. A 2008, 146A:1911-1916.
53. Girgenti M.J., Collier E., Sathyanesan M., Su X.W., Newton S.S. Characterization of electroconvulsive seizure-induced TIMP-1 and MMP-9 in hippocampal vasculature. Int. J. Neuropsychopharmacol. 2011, 14(4):535-544.
54. Goffin K., Dedeurwaerdere S., Van Laere K., Van Paesschen W. Neuronuclear assessment of patients with epilepsy. Semin. Nucl. Med. 2008, 38:227-239.
55. Goffin K., Van Paesschen W., Dupont P., Van Laere K. Longitudinal microPET imaging of brain glucose metabolism in rat lithium-pilocarpine model of epilepsy. Exp. Neurol. 2009, 217:205-209.
56. Gorter J.A., Van Vliet E.A., Rauwerda H., Breit T., Stad R., Van Schaik L., Vreugdenhil E., Redeker S., Hendriksen E., Aronica E., Da Silva F.H.L., Wadman W.J. Dynamic changes of proteases and protease inhibitors revealed by microarray analysis in CA3 and entorhinal cortex during epileptogenesis in the rat. Epilepsia 2007, 48(Suppl. 5):53-64.
57. Grooms S.Y., Jones L.S. RGDS tetrapeptide and hippocampal in vitro kindling in rats: evidence for integrin-mediated physiological stability. Neurosci. Lett. 1997, 231(3):139-142.
58. Guo Y., Gao F., Wang S., Ding Y., Zhang H., Wang J., Ding M.P. In vivo mapping of temporospatial changes in glucose utilization in rat brain during epileptogenesis: an 18F-fluorodeoxyglucose-small animal positron emission tomography study. Neuroscience 2009, 162:972-979.
59. Gurevicius K., Gureviciene I., Valjakka A., Schachner M., Tanila H. Enhanced cortical and hippocampal neuronal excitability in mice deficient in the extracellular matrix glycoprotein tenascin-R. Mol. Cell. Neurosci. 2004, 25:515-523.
60. Gur-Wahnon D., Mizrachi T., Maaravi-Pinto F.Y., Lourbopoulos A., Grigoriadis N., Higazi A.A., Brenner T. The plasminogen activator system: involvement in central nervous system inflammation and a potential site for therapeutic intervention. J. Neuroinflammation 2013, 10:124.
61. Hara H. Autism and epilepsy: a retrospective follow-up study. Brain Dev. 2007, 29:486-490.
62. Hartmann G., Prospero T., Brinkmann V., Ozcelik C., Winter G., Hepple J., et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 1998, 8:125-134.
63. Herndon M.E., Stipp C.S., Lander A.D. Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding. Glycobiology 1999, 9:143-155.
64. Hienola A., Tumova S., Kulesskiy E., Rauvala H. N-syndecan deficiency impairs neural migration in brain. J. Cell Biol. 2006, 174:569-580.
65. Hoffmann K., Sivukhina E., Potschka H., Schachner M., Löscher W., Dityatev A. Retarded kindling progression in mice deficient in the extracellular matrix glycoprotein tenascin-R. Epilepsia 2009, 50:859-869.
66. Hua J., Dobrucki L.W., Sadeghi M.M., Zhang J., Bourke B.N., Cavaliere P., Song J., Chow C., Jahanshad N., van Royen N., Buschmann I., Madri J.A., Mendizabal M., Sinusas A.J. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation 2005, 111:3255-3260.
67. Hyde T.M., Weinberger D.R. Seizures and schizophrenia. Schizophr. Bull. 1997, 23:611-622.
68. Ijff D.M., Aldenkamp A.P. Cognitive side-effects of antiepileptic drugs in children. Handb. Clin. Neurol. 2013, 111:707-718.
69. Irani S.R., Alexander S., Waters P., Kleopa K.A., Pettingill P., Zuliani L., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
70. Irani S.R., Michell A.W., Lang B., Pettingill P., Waters P., Johnson M.R., et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann. Neurol. 2011, 69:892-900.
71. Irie F., Badie-Mahdavi H., Yamaguchi Y. Autism-like socio-communicative deficits and stereotypies in mice lacking heparan sulfate. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:5052-5056.
72. Iyer A.M., Zurolo E., Boer K., Baayen J.C., Giangaspero F., Arcella A., Di Gennaro G.C., Esposito V., Spliet W.G., van Rijen P.C., Troost D., Gorter J.A., Aronica E. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies. Neuroscience 2010, 167(3):929-945.
73. Jack S. Review: existing epidemiological evidence does not show an association between mumps, measles, and rubella vaccination and autism. Evid. Based Nurs. 2004, 7:25.
74. Jaworski J., Biedermann I.W., Lapinska J., Szklarczyk A., Figiel I., Konopka D., Nowicka D., Filipkowski R.K., Hetman M., Kowalczyk A., Kaczmarek L. Neuronal excitation-driven and AP-1-dependent activation of tissue inhibitor of metalloproteinases-1 gene expression in rodent hippocampus. J. Biol. Chem. 1999, 274(40):28106-28112.
75. Jourquin J., Tremblay E., Bernard A., Charton G., Chaillan F.A., Marchetti E., Roman F.S., Soloway P.D., Dive V., Yiotakis A., Khrestchatisky M., Rivera S. Tissue inhibitor of metalloproteinases-1 (TIMP-1) modulates neuronal death, axonal plasticity, and learning and memory. Eur. J. Neurosci. 2005, 22(10):2569-2578.
76. Jupp B., Williams J., Binns D., Hicks R.J., Cardamone L., Jone s.N., Rees S., O'Brien T.J. Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE. Epilepsia 2012, 53:1233-1244.
77. Kalachikov S., Evgrafov O., Ross B., Winawer M., Barker-Cummings C., Martinelli Boneschi F., et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat. Genet. 2002, 30:335-341.
78. Kalinowski L., Dobrucki L.W., Meoli D.F., Dione D.P., Sadeghi M.M., Madri J.A., Sinusas A.J. Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction. J. Appl. Physiol. (1985). 2008, 104:1504-1512.
79. Kawaguchi S.Y., Hirano T. Integrin alpha3beta1 suppresses long-term potentiation at inhibitory synapses on the cerebellar Purkinje neuron. Mol. Cell. Neurosci. 2006, 31(3):416-426.
80. Kim H.J., Fillmore H.L., Reeves T.M., Phillips L.L. Elevation of hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis. Exp. Neurol. 2005, 92(1):60-72.
81. Kim G.W., Kim H.J., Cho K.J., Kim H.W., Cho Y.J., Lee B.I. The role of MMP-9 in integrin-mediated hippocampal cell death after pilocarpine-induced status epilepticus. Neurobiol. Dis. 2009, 36(1):169-180.
82. Kiyan J., Kiyan R., Haller H., Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-beta. EMBO J. 2005, 24(10):1787-1797.
83. Kobayashi E., Santos N.F., Torres F.R., Secolin R., Sardinha L.A.C., Lopez-Cendes I., et al. Magnetic resonance imaging abnormalities in familial temporal lobe epilepsy with auditory auras. Arch. Neurol. 2003, 60:1546-1551.
84. Konopka A., Grajkowska W., Ziemianska K., Roszkowski M., Daszkiewicz P., Rysz A., Marche l.A., Koperski L., Wilczynski G.M., Dzwonek J. Matrix metalloproteinase-9 (MMP-9) in human intractable epilepsy caused by focal cortical dysplasia. Epilepsy Res. 2013, 104(1-2):45-58.
85. Kopjas N.N., Jones R.T., Bany B., Patrylo P.R. Reeler mutant mice exhibit seizures during recovery from isoflurane-induced anesthesia. Epilepsy Res. 2006, 69:87-91.
86. Korotchenko S., Cingolani L.A., Kuznetsova T., Bologna L.L., Chiappalone M., Dityatev A. Modulation of network activity and induction of homeostatic synaptic plasticity by enzymatic removal of heparan sulfates. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369(1654):1471-2970.
87. Kunapuli P., Kasyapa C.S., Hawthorn L., Cowell J.K. LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J. Biol. Chem. 2004, 279:23151-23157.
88. Lahtinen L., Lukasiuk K., Pitkänen A. Increased expression and activity of urokinase-type plasminogen activator during epileptogenesis. Eur. J. Neurosci. 2006, 24(7):1935-1945.
89. Lahtinen L., Huusko N., Myöhänen H., Lehtivarjo A.K., Pellinen R., Turunen M.P., Ylä-Herttuala S., Pirinen E., Pitkänen A. Expression of urokinase-type plasminogen activator receptor is increased during epileptogenesis in the rat hippocampus. Neuroscience 2009, 163(1):316-328.
90. Lahtinen L., Ndode-Ekane X.E., Barinka F., Akamine Y., Esmaeil i.M.H., Rantala J., Pitkänen A. Urokinase-type plasminogen activator regulates neurodegeneration and neurogenesis but not vascular changes in the mouse hippocampus after status epilepticus. Neurobiol. Dis. 2010, 37(3):692-703.
91. Lai M., Huijbers M.G.M., Lancaster E., Graus F., Bataller L., Balice-Gordon R., et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010, 9:776-785.
92. Leigh M.J., Nguyen D.V., Mu Y., Winarni T.I., Schneider A., Chechi T., et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J. Dev. Behav. Pediatr. 2013, 34:147-155.
93. Leonardi E., Andreazza S., Vanin S., Busolin G., Nobile C., Tosatto S.C.E. A computational model of the LGI1 protein suggests a common binding site for ADAM proteins. PLoS One 2011, 6:e18142.
94. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci. 2005, 6:312-324.
95. Li H., Yamagata T., Mori M., Momoi M.Y. Association of autism in two patients with hereditary multiple exostoses caused by novel deletion mutations of EXT1. J. Hum. Genet. 2002, 47:262-265.
96. Li S., Yu S., Zhang C., Shu H., Liu S., An N., Yang M., Yin Q., Yang H. Increased expression of matrix metalloproteinase 9 in cortical lesions from patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. Brain Res. 2012, 1453:46-55.
97. Lino N., Fiore L., Rapacioli M., Teruel L., Flores V., Scicolone G., Sánchez V. uPA-uPAR molecular complex is involved in cell signaling during neuronal migration and neuritogenesis. Dev. Dyn. 2014, 243(5):676-689.
98. Liu X.-B., Murray K.D., Jones E.G. Switching of NMDA receptor 2A and 2B subunits at thalamic and cortical synapses during early postnatal development. J. Neurosci. 2004, 24:8885-8895.
99. Liu Y., Cao D.J., Sainz I.M., Guo Y.L., Colman R.W. The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization. Am. J. Physiol. Cell Physiol. 2008, 295(1):C257-C267.
100. Liu Y., Pixley R., Fusaro M., Godoy G., Kim E., Bromberg M.E., Colman R.W. Cleaved high-molecular-weight kininogen and its domain 5 inhibit migration and invasion of human prostate cancer cells through the epidermal growth factor receptor pathway. Oncogene 2009, 28(30):2756-2765.
101. Liu B., Zhang B., Wan g.T., Liang Q.C., Jing X.R., Zheng J., Wang C., Meng Q., Wang L., Wang W., Guo H., You Y., Zhang H., Gao G.D. Increased expression of urokinase-type plasminogen activator receptor in the frontal cortex of patients with intractable frontal lobe epilepsy. J. Neurosci. Res. 2010, 88(12):2747-2754.
102. Llinas P., Le Du M.H., Gårdsvoll H., Danø K., Ploug M., Gilquin B., Stura E.A., Ménez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005, 24(9):1655-1663.
103. Lukasiuk K., Kontula L., Pitkänen A. cDNA profiling of epileptogenesis in the rat brain. Eur. J. Neurosci. 2003, 17(2):271-279.
104. Madsen C.D., Ferraris G.M., Andolfo A., Cunningham O., Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 2007, 177(5):927-939.
105. Malla R., Gopinath S., Alapati K., Gondi C.S., Gujrati M., Dinh D.H., Mohanam S., Rao J.S. Downregulation of uPAR and cathepsin B induces apoptosis via regulation of Bcl-2 and Bax and inhibition of the PI3K/Akt pathway in gliomas. PLoS One 2010, 5(10).
106. Marrone M.C., Marinelli S., Biamonte F., Keller F., Sgobio C.A., Ammassari-Teule M., et al. Altered cortico-striatal synaptic plasticity and related behavioural impairments in reeler mice. Eur. J. Neurosci. 2006, 24:2061-2070.
107. Mars W.M., Liu M.L., Kitson R.P., Goldfarb R.H., Gabauer M.K., Michalopoulos G.K. Immediate early detection of urokinase receptor after partial hepatectomy and its implications for initiation of liver regeneration. Hepatology 1995, 21:1695-1701.
108. Matusiak N., van Waarde A., Bischoff R., Oltenfreiter R., van de Wiele C., Dierckx R., Elsinga P.H. Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Curr. Pharm. Des. 2013, 19:4647-4672.
109. Mauney S.A., Athanas K.M., Pantazopoulos H., Shaskan N., Passeri E., Berretta S., et al. Developmental pattern of perineuronal nets in the human prefrontal cortex and their deficit in schizophrenia. Biol. Psychiatry 2013, 74:427-435.
110. Mayville E.A., Matson J.L. Assessment of seizures and related symptomatology in persons with mental retardation. Behav. Modif. 2004, 28:678-693.
111. McRae P.A., Porter B.E. The perineuronal net component of the extracellular matrix in plasticity and epilepsy. Neurochem. Int. 2012, 61:963-972.
112. McRae P.A., Baranov E., Rogers S.L., Porter B.E. Persistent decrease in multiple components of the perineuronal net following status epilepticus. Eur. J. Neurosci. 2012, 36:3471-3482.
113. Meoli D.F., Sadeghi M.M., Krassilnikova S., Bourke B.N., Giordano F.J., Dione D.P., Su H., Edwards D.S.L.S., Harris T.D., Madri J.A., Zaret B.L., Sinusas A.J. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J. Clin. Invest. 2004, 113:1684-1691.
114. Mercier F., Cho Kwon Y., Kodama R. Meningeal/vascular alterations and loss of extracellular matrix in the neurogenic zone of adult BTBR T+ tf/J mice, animal model for autism. Neurosci. Lett. 2011, 498:173-178.
115. Mercier F., Kwon Y.C., Douet V. Hippocampus/amygdala alterations, loss of heparan sulfates, fractones and ventricle wall reduction in adult BTBR T+ tf/J mice, animal model for autism. Neurosci. Lett. 2012, 506:208-213.
116. Meyza K.Z., Blanchard D.C., Pearson B.L., Pobbe R.L., Blanchard R.J. Fractone-associated N-sulfated heparan sulfate shows reduced quantity in BTBR T+tf/J mice: a strong model of autism. Behav. Brain Res. 2012, 228:247-253.
117. Michaluk P., Kolodziej L., Mioduszewska B., Wilczynski G.M., Dzwonek J., Jaworski J., Gorecki D.C., Ottersen O.P., Kaczmarek L. β-Dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J. Biol. Chem. 2007, 282(22):16036-16041.
118. Michaluk P., Mikasova L., Groc L., Frischknecht R., Choquet D., Kaczmarek L. Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin β1 signaling. J. Neurosci. 2009, 29(18):6007-6012.
119. Michaluk P., Wawrzyniak M., Alot P., Szczot M., Wyrembek P., Mercik K., Medvedev N., Wilczek E., De Roo M., Zuschratter W., Muller D., Wilczynski G.M., Mozrzymas J.W., Stewart M.G., Kaczmarek L., Wlodarczyk J. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J. Cell Sci. 2011, 124(Pt 19):3369-3380.
120. Miljkovic-Licina M., Hammel P., Garrido-Urbani S., Bradfield P.F., Szepetowski P., Imhof B.A. Sushi repeat protein X-linked 2, a novel mediator of angiogenesis. FASEB J. 2009, 23(12):4105-4116.
121. Mizoguchi H., Nakade J., Tachibana M., Ibi D., Someya E., Koike H., Kamei H., Nabeshima T., Itohara S., Takuma K., Sawada M., Sato J., Yamada K. Matrix metalloproteinase-9 contributes to kindled seizure development in pentylenetetrazole-treated mice by converting pro-BDNF to mature BDNF in the hippocampus. J. Neurosci. 2011, 31(36):12963-12971.
122. Monyer H., Burnashev N., Laurie D.J., Sakmann B., Seeburg P.H. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994, 12:529-540.
123. Morante-Redolat J.M., Gorostidi-Pagola A., Piquer-Sirerol S., Sáenz A., Poza J.J., Galán J., et al. Mutations in the LGI1/Epitempin gene on 10q24 cause autosomal dominant lateral temporal epilepsy. Hum. Mol. Genet. 2002, 11:1119-1128.
124. Morawski M., Dityatev A., Hartlage-Rübsamen M., Blosa M., Holzer M., Flach K., Pavlica S., Dityateva G., Grosche J., Brückner G., Schachner M. Tenascin-R promotes assembly of the extracellular matrix of perineuronal nets via clustering of aggrecan. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014, 369(1654):1471-2970.
125. Nagai N., Okada K., Kawao N., Ishida C., Ueshima S., Collen D., Matsuo O. Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke. Neurosci. Lett. 2008, 432(1):46-49.
126. Nagy V., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., Costa R.M., Silva A.J., Kaczmarek L., Huntley G.W. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J. Neurosci. 2006, 26(7):1923-1934.
127. Ndode-Ekane X.E., Pitkänen A. Urokinase-type plasminogen activator receptor modulates epileptogenesis in mouse model of temporal lobe epilepsy. Mol. Neurobiol. 2013, 47(3):914-937.
128. Nedivi E., Hevroni D., Naot D., Israell D., Citri Y. Numerous candidate plasticity-related genes revealed by differential cDNA cloning. Nature 1993, 363(6431):718-722.
129. Nouel D., Burt M., Zhang Y., Harvey L., Boksa P. Prenatal exposure to bacterial endotoxin reduces the number of GAD67- and reelin-immunoreactive neurons in the hippocampus of rat offspring. Eur. Neuropsychopharmacol. 2012, 22:300-307.
130. Ohkawa T., Fukata Y., Yamasaki M., Miyazaki T., Yokoi N., Takashima H., et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J. Neurosci. 2013, 33:18161-18174.
131. Ono T., Galanopoulou A.S. Epilepsy and epileptic syndrome. Adv. Exp. Med. Biol. 2012, 724:99-113.
132. Orlando C., Ster J., Gerber U., Fawcett J.W., Raineteau O. Perisynaptic chondroitin sulfate proteoglycans restrict structural plasticity in an integrin-dependent manner. J. Neurosci. 2012, 32:18009-18017.
133. Ottman R., Winawer M.R., Kalachikov S., Barker-Cummings C., Gilliam T.C., Pedley T.A., et al. LGI1 mutations in autosomal dominant partial epilepsy with auditory features. Neurology 2004, 62:1120-1126.
134. Ottman R., Rosenberger L., Bagic A., Kamberakis K., Ritzl E.K., Wohlschlager A.M., et al. Altered language processing in autosomal dominant partial epilepsy with auditory features. Neurology 2008, 71:1973-1980.
135. Owuor K., Harel N.Y., Englot D.J., Hisama F., Blumenfeld H., Strittmatter S.M. LGI1-associated epilepsy through altered ADAM23-dependent neuronal morphology. Mol. Cell. Neurosci. 2009, 42:448-457.
136. Pantazopoulos H., Woo T.U., Lim M.P., Lange N., Berretta S. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch. Gen. Psychiatry 2010, 67:155-166.
137. Patrikelis P., Angelakis E., Gatzonis S. Neurocognitive and behavioral functioning in frontal lobe epilepsy: a review. Epilepsy Behav. 2009, 14:19-26.
138. Paul R., Winkler F., Bayerlein I., Popp B., Pfister H.W., Koedel U. Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis. J. Infect. Dis. 2005, 191(5):776-782.
139. Pearson B.L., Corley M.J., Vasconcellos A., Blanchard D.C., Blanchard R.J. Heparan sulfate deficiency in autistic postmortem brain tissue from the subventricular zone of the lateral ventricles. Behav. Brain Res. 2013, 243:138-145.
140. Peixoto R.T., Kunz P.A., Kwon H., Mabb A.M., Sabatini B.L., Philpot B.D., Ehlers M.D. Transsynaptic signaling by activity-dependent cleavage of neuroligin-1. Neuron 2012, 76(2):396-409.
141. Persico A.M., D'agruma L., Maiorano N., Totaro A., Militerni R., Bravaccio C., et al. Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder. Mol. Psychiatry 2001, 6:150-159.
142. Persson M., Kjaer A. Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. Clin. Physiol. Funct. Imaging 2013, 33:329-337.
143. Piao X., Hill R.S., Bodell A., Chang B.S., Basel-Vanagaite L., Straussberg R., Dobyns W.B., Qasrawi B., Winter R.M., Innes A.M., Voit T., Ross M.E., Michaud J.L., Déscarie J.C., Barkovich A.J., Walsh C.A. G protein-coupled receptor-dependent development of human frontal cortex. Science 2004, 303(5666):2033-2036.
144. Pichler B.J., Kneilling M., Haubner R., Braumüller H., Schwaiger M., Röcken M., Weber W.A. Imaging of delayed-type hypersensitivity reaction by PET and 18F-galacto-RGD. J. Nucl. Med. 2005, 46:184-189.
145. Piepoli T., Jakupoglu C., Gu W., Lualdi E., Suarez-Merino B., Poliani P.L., et al. Expression studies in gliomas and glial cells do not support a tumor suppressor role for LGI1. Neuro Oncol. 2006, 8:96-108.
146. Pinkstaff J.K., Lynch G., Gall C.M. Localization and seizure-regulation of integrin beta 1 mRNA in adult rat brain. Brain Res. Mol. Brain Res. 1998, 55(2):265-276.
147. Pitkänen A., Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav. 2009, 14(Suppl. 1):16-25.
148. Pitkänen A., Nehlig A., Brooks-Kayal A.R., Dudek F.E., Friedman D., Galanopoulou A.S., Jensen F.E., Kaminski R.M., Kapur J., Klitgaard H., Löscher W., Mody I., Schmidt D. Issues related to development of antiepileptogenic therapies. Epilepsia 2013, 54(Suppl. 4):35-43.
149. Powell E.M., Campbell D.B., Stanwood G.D., Davis C., Noebels J.L., Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J. Neurosci. 2003, 23:622-631.
150. Quirico-Santos T., Nascimento Mello A., Casimiro Gomes A., de Carvalho L.P., de Souza J.M., Alves-Leon S. Increased metalloprotease activity in the epileptogenic lesion-lobectomy reduces metalloprotease activity and urokinase-type uPAR circulating levels. Brain Res. 2013, 1538:172-181.
151. Resnati M., Pallavicini I., Wang J.M., Oppenheim J., Serhan C.N., Romano M., Blasi F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. U.S.A. 2002, 99(3):1359-1364.
152. Rice D., Barone S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ. Health Perspect. 2000, 108(Suppl. 3):511-533.
153. Rivera S., Khrestchatisky M., Kaczmarek L., Rosenberg G.A., Jaworski D.M. Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?. J. Neurosci. 2010, 30(46):15337-15357.
154. Roll P., Rudolf G., Pereira S., Royer B., Scheffer I.E., Massacrier A., et al. SRPX2 mutations in disorders of language cortex and cognition. Hum. Mol. Genet. 2006, 15:1195-1207.
155. Royer-Zemmour B., Ponsole-Lenfant M., Gara H., Rol l.P., Lévêque C., Massacrier A., Ferracci G., Cillario J., Robaglia-Schlupp A., Vincentelli R., Cau P., Szepetowski P. Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. Hum. Mol. Genet. 2008, 17(23):3617-3630.
156. Sagane K., Ishihama Y., Sugimoto H. LGI1 and LGI4 bind to ADAM22, ADAM23 and ADAM11. Int. J. Biol. Sci. 2008, 4:387-396.
157. Saghatelyan A.K., Dityatev A., Schmidt S., Schuster T., Bartsch U., Schachner M. Reduced perisomatic inhibition, increased excitatory transmission, and impaired long-term potentiation in mice deficient for the extracellular matrix glycoprotein tenascin-R. Mol. Cell. Neurosci. 2001, 17:226-240.
158. Sakatani S., Seto-Ohshima A., Shinohara Y., Yamamoto Y., Yamamoto H., Itohara S., Hirase H. Neural-activity-dependent release of S100B from astrocytes enhances kainate-induced gamma oscillations in vivo. J. Neurosci. 2008, 28:10928-10936.
159. Scheel H., Tomiuk S., Hofmann K. A common protein interaction domain links two recently identified epilepsy genes. Hum. Mol. Genet. 2002, 11:1757-1762.
160. Schrigten D., Breyholz H.J., Wagner S., Hermann S., Schober O., Schäfers M., Haufe G., Kopka K. A new generation of radiofluorinated pyrimidine-2,4,6-triones as MMP-targeted radiotracers for positron emission tomography. J. Med. Chem. 2012, 55:223-232.
161. Schulte U., Thumfart J.-O., Klöcker N., Sailer C.A., Bildl W., Biniossek M., et al. The epilepsy-linked Lgi1 protein assembles into presynaptic Kv1 channels and inhibits inactivation by Kvbeta1. Neuron 2006, 49:697-706.
162. Seltzer M.M., Baker M.W., Hong J., Maenner M., Greenberg J., Mandel D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012, 159B:589-597.
163. Senechal K.R., Thaller C., Noebels J.L. ADPEAF mutations reduce levels of secreted LGI1, a putative tumor suppressor protein linked to epilepsy. Hum. Mol. Genet. 2005, 14:1613-1620.
164. Sheng M., Cummings J., Roldan L.A., Jan Y.N., Jan L.Y. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 1994, 368:144-147.
165. Shultz S.R., O'Brien T.J., Stefanidou M., Kuzniecky R.I. Neuroimaging the epileptogenic process. Neurotherapeutics 2014, 11:347-357.
166. Siller S.S., Broadie K. Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. Neural Plast. 2012, 2012:124548.
167. Silva J., Wang G., Cowell J.K. The temporal and spatial expression pattern of the LGI1 epilepsy predisposition gene during mouse embryonic cranial development. BMC Neurosci. 2011, 12:43.
168. Sipkins D.A., Cheresh D.A., Kazemi M.R., Sipkins D.A., Cheresh D.A., Kazemi M.R. Detection of tumor angiogenesis in vivo by alphaV-beta3-targeted magnetic resonance imaging. Nat. Med. 1998, 4:623-626.
169. Sirerol-Piquer M.S., Ayerdi-Izquierdo A., Morante-Redolat J.M., Herranz-Pérez V., Favell K., Barker P.A., et al. The epilepsy gene LGI1 encodes a secreted glycoprotein that binds to the cell surface. Hum. Mol. Genet. 2006, 15:3436-3445.
170. Skaar D.A., Shao Y., Haines J.L., Stenger J.E., Jaworski J., Martin E.R., et al. Analysis of the RELN gene as a genetic risk factor for autism. Mol. Psychiatry 2005, 10:563-571.
171. Smith H.W., Marshall C.J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell Biol. 2010, 11(1):23-36.
172. Smith H.W., Marra P., Marshal l.C.J. uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J. Cell Biol. 2008, 182(4):777-790.
173. Sommer B.R., Mitchell E.L., Wroolie T.E. Topiramate: effects on cognition in patients with epilepsy, migraine headache and obesity. Ther. Adv. Neurol. Disord. 2013, 6:211-227.
174. Spalice A., Parisi P., Nicita F., Pizzardi G., Del Balzo F., Iannetti P. Neuronal migration disorders: clinical, neuroradiologic and genetics aspects. Acta Paediatr. 2009, 98(3):421-433.
175. Staub E., Pérez-Tur J., Siebert R., Nobile C., Moschonas N.K., Deloukas P., et al. The novel EPTP repeat defines a superfamily of proteins implicated in epileptic disorders. Trends Biochem. Sci. 2002, 27:441-444.
176. Striano P., Busolin G., Santulli L., Leonardi E., Coppola A., Vitiello L., et al. Familial temporal lobe epilepsy with psychic auras associated with a novel LGI1 mutation. Neurology 2011, 76:1173-1176.
177. Suenaga N., Ichiyama T., Kubota M., Isumi H., Tohyama J., Furukawa S. Roles of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in acute encephalopathy following prolonged febrile seizures. J. Neurol. Sci. 2008, 266(1-2):126-130.
178. Takács E., Nyilas R., Szepes i.Z., Baracskay P., Karlsen B., Røsvold T., Bjørkum A.A., Czurkó A., Kovács Z., Kékesi A.K., Juhász G. Matrix metalloproteinase-9 activity increased by two different types of epileptic seizures that do not induce neuronal death: a possible role in homeostatic synaptic plasticity. Neurochem. Int. 2010, 56(6-7):799-809.
179. Tessa C., Michelucci R., Nobile C., Giannelli M., Della Nave R., Testoni S., et al. Structural anomaly of left lateral temporal lobe in epilepsy due to mutated LGI1. Neurology 2007, 69:1298-1300.
180. Thomas R., Favell K., Morante-Redolat J., Pool M., Kent C., Wright M., et al. LGI1 is a Nogo receptor 1 ligand that antagonizes myelin-based growth inhibition. J. Neurosci. 2010, 30:6607-6612.
181. Tian L., Stefanidakis M., Ning L., Van Lint P., Nyman-Huttunen H., Libert C., Itohara S., Mishina M., Rauvala H., Gahmberg C.G. Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. J. Cell Biol. 2007, 178(4):687-700.
182. Tinnes S., Ringwald J., Haas C.A. TIMP-1 inhibits the proteolytic processing of Reelin in experimental epilepsy. FASEB J. 2013, 27(7):2542-2552.
183. Tsiapa I., Loudos G., Varvarigou A., Fragogeorgi E., Psimadas D., Tsotakos T., Xanthopoulos S., Mihailidis D., Bouziotis P., Nikiforidis G.C., Kagadis G.C. Biological evaluation of an ornithine-modified 99mTc-labeled RGD peptide as an angiogenesis imaging agent. Nucl. Med. Biol. 2013, 40:262-272.
184. Vedunova M., Sakharnova T., Mitroshina E., Perminova M., Pimashkin A., Zakharov Y., Dityatev A., Mukhina I. Seizure-like activity in hyaluronidase-treated dissociated hippocampal cultures. Front. Cell. Neurosci. 2013, 7:149.
185. Vivash L., Gregoire M.C., Lau E.W., Ware R.E., Binns D., Roselt P., Bouilleret V., Myers D.E., Cook M.J., Hicks R.J., O'Brien T.J. 18F-flumazenil: a gamma-aminobutyric acid A-specific PET radiotracer for the localization of drug-resistant temporal lobe epilepsy. J. Nucl. Med. 2013, 54:1270-1277.
186. Wagner S., Breyholz H.J., Faust A., Höltke C., Levkau B., Schober O., Schäfers M., Kopka K. Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr. Med. Chem. 2006, 13:2819-2838.
187. Wang X., Jung J., Asahi M., Chwang W., Russo L., Moskowitz M.A., Dixon C.E., Fini M.E., Lo E.H. Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J. Neurol. Sci. 2000, 20(18):7037-7042.
188. Wang X.B., Bozdagi O., Nikitczuk J.S., Zu W.Z., Zhou Q., Huntley G.W. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(49):19520-19525.
189. Wang L.W., Berry-Kravis E., Hagerman R.J. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 2010, 7:264-274.
190. Wang J., Barstein J., Ethridge L.E., Mosconi M.W., Takarae Y., Sweeney J.A. Resting state EEG abnormalities in autism spectrum disorders. J. Neurodev. Disord. 2013, 5:24.
191. Wenzel H.J., Vacher H., Clark E., Trimmer J.S., Lee A.L., Sapolsky R.M., et al. Structural consequences of Kcna1 gene deletion and transfer in the mouse hippocampus. Epilepsia 2007, 48:2023-2046.
192. Wilczynski G.M., Konopacki F.A., Wilczek E., Lasiecka Z., Gorlewicz A., Michaluk P., Wawrzyniak M., Malinowska M., Okulski P., Kolodziej L.R., Konopka W., Duniec K., Mioduszewska B., Nikolaev E., Walczak A., Owczarek D., Gorecki D.C., Zuschratter W., Ottersen O.P., Kaczmarek L. Important role of matrix metalloproteinase 9 in epileptogenesis. J. Cell Biol. 2008, 180(5):1021-1035.
193. Winningham-Major F., Staecker J.L., Barger S.W., Coats S., Van Eldik L.J. Neurite extension and neuronal survival activities of recombinant S100 beta proteins that differ in the content and position of cysteine residues. J. Cell Biol. 1989, 109:3063-3071.
194. Wu Y., Wang X.F., Mo X.A., Li J.M., Yuan J., Zhen g.J.O., Feng Y., Tang M. Expression of laminin β1 and integrin α2 in the anterior temporal neocortex tissue of patients with intractable epilepsy. Int. J. Neurosci. 2011, 121(6):323-328.
195. Zhou Y.-D., Lee S., Jin Z., Wright M., Smith S.E.P., Anderson M.P. Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsy. Nat. Med. 2009, 15:1208-1214.
196. Zuberi S.M., Eunson L.H., Spauschus A., De Silva R., Tolmie J., Wood N.W., et al. A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain 1999, 122(Pt 5):817-825.